AI Article Synopsis
- Immunotherapy is an effective cancer treatment but can lead to immune-related adverse events (irAEs), with skin toxicities being the most common.
- Bullous pemphigoid, a rare but potentially life-threatening skin condition, can occur after immunotherapy treatments like PD-1 inhibitors in colorectal cancer patients.
- In a reported case, a patient with pMMR/MSS colorectal cancer experienced bullous pemphigoid but improved significantly after treatment, with no new skin lesions and a partial remission of cancer lasting over 8 months.
Article Abstract
Immunotherapy has become a very effective treatment for many cancers. It has a unique set of immune system-related adverse effects, collectively known as immune-related adverse events (irAEs). Skin toxicities are the most common irAEs, of which bullous pemphigoid, although rare, is potentially life-threatening and affects patients' survival. In this article, we report the treatment of bullous pemphigoid caused by programmed cell death protein-1 (PD-1) in a case of proficient mismatch repair (pMMR)/microsatellite stable (MSS) colorectal cancer. No significant adverse effects were observed in the patient after methylprednisone was tapered to 4 mg twice a day. No new skin lesions occurred recently in the patient and the original skin lesions healed. In particular, the patient's immunotherapy was not stopped and the best outcome was a partial remission of the disease, lasting for more than 8 months.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043161 | PMC |
| http://dx.doi.org/10.3389/fonc.2023.1124730 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!